Lp-PLA2 Inhibition-The Atherosclerosis Panacea?

Pharmaceuticals

Volumn 3, Issue 5, 2010, Pages 1360-1373

  Karakas, Mahir ^a   Koenig, Wolfgang ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Atherosclerosis; Inflammation; Oxidative processes; Specific inhibition

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATORVASTATIN; DARAPLADIB; PLACEBO;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; GENE EXPRESSION; GERIATRIC PATIENT; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; MIDDLE AGED; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 77954928393     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3051360     Document Type: Review

References (59)

1. Asano, K.; Okamoto, S., Fukunaga, K.; Shiomi, T.; Mori, T.; Iwata, M.; Ikeda, Y.; Yamaguchi, K. Cellular sources of platelet-activating-factor acetylhydrolase activity in plasma. Biochem. Biophys. Res. Commun. 1999, 261, 511-514.
2. Stafforini, D.M.; Elstad, M.R.; McIntyre, T.M.; Zimmerman, G.A.; Prescott, S.M. Human macrophages secrete platelet-activating factor acetylhydrolase. J. Biol. Chem. 1990, 265, 9682-9687.
3. Venable, M.E.; Zimmerman, G.A.; McIntyre, T.M.; Prescott, S.M. Platelet-activating factor: a phospholipid autacoid with diverse actions. J. Lipid Res. 1993, 34, 691-702.
4. Min, J.H.; Jain, M.K.; Wilder, C.; Paul, L.; Apitz-Castro, R.; Aspleaf, D.C.; Gelb, M.H. Membrane-bound plasma platelet activating factor acetylhydrolase acts on substrate in the aqueous phase. Biochemistry 1999, 38, 12935-12942.
5. Stafforini, D.M.; Tjoelker, L.W.; McCormick, S.P.; Vaitkus, D.; McIntyre, T.M.; Gray, P.W.; Young, S.G.; Prescott, S.M. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low-density lipoprotein. J. Biol. Chem. 1999, 274, 7018-7024.
6. Macphee, C.H.; Moores, K.E.; Boyd, H.F.; Dhanak, D., Ife, R.J.; Leach, C.A.; Leake, D.S.; Milliner, K.J.; Patterson, R.A.; Suckling, K.E.; Tew, D.G.; Hickey, D.M. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem. J. 1999, 338, 479-487.
7. Hannson, G.K. Mechanisms of disease-Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352, 1685-1695.
8. Khan-Merchant, N.; Penumetcha, M.; Meilhac, O.; Parthasarathy, S. Oxidized fatty acids promote atherosclerosis only in the presence of dietary cholesterol in low-density lipoprotein receptor knockout mice. J. Nutr. 2002, 132, 3256-62.
9. Bäck, M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc. Drugs Ther. 2009, 23, 41-48.
10. Balsinde, J.; Winstead, M.V.; Dennis, E.A. Phospholipase A (2) regulation of arachidonic acid mobilization. FEBS Lett. 2002, 531, 2-6.
11. Matsumo, T.; Kobayashi, T.; Kamata, K. Role of lysophoshatidylcholine (LPC) in atheroclerosis. Curr. Med. Chem. 2007, 14, 3209-3220.
12. Schmitz, G.; Ruebsaamen, K. Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis 2009, 10-18.
13. Hakkinen, T.; Luoma, J.S.; Hiltunen, M.O.; Macphee, C.H.; Milliner, K.J.; Patel, L.; Rice, S.Q.; Tew, D.G.; Karkola, K.; Ylä-Herttuala, S. Lipoprotein-associated phospholipase 2, a plateletactivating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 2909-2917.
14. Kume, N.; Cybulski, M.I.; Gimbrone, Jr. M.A. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest. 1992, 90, 1138-1144.
15. Rong, J.X.; Berman, J.W.; Taubman, M.B.; Fisher, E.A. Lysophosphatidylcholine stimulates monocyte chemoattractant protein-1 gene expression in rat aortic smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 1617-1623.
16. Takahara, N.; Kashiwaga, A.; Maegawa, H.; Shigeta, Y. Lysophosphatidylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells. Metabolism 1996, 45, 559-564.
17. Liu-Wu, Y.; Hurt-Camejo, E.; Wiklund, O. Lysophosphatidylcholine induces the production of IL-1beta by human monocytes. Atherosclerosis 1998, 137, 351-357.
18. Ousman, S.S.; David, S. Lysophosphatidylcholine induces rapid recruitment and activation of macrophages in the adult mouse spinal cord. Glia 2000, 30, 92-104.
19. Macphee, C.H.; Nelsonj, J.J.; Zalewski, A. Lipoprotein-associated phospholipase A2 as a target of therapy. Curr. Opin. Lipidol. 2005, 16, 4442-4446.
20. Tjoelker, L.W.; Wilder, C.; Eberhardt, C.; Stafforini, D.M.; Dietsch, G.; Schimpf, B.; Hooper, S.; Le Trong, H.; Cousens, L.S.; Zimmerman, G.A. Anti-inflammatory properties of a plateletactivating factor acetylhydrolase. Nature 1995, 374, 549-553.
21. Lerman, A, McConnell, J.P. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor? Am. J. Cardiol. 2008, 101, 11F-22F.
22. Theilmeier, G.; De Geest, B.; Van Veldhofen, P.P.; Stengel, D.; Michiels, C.; Lox, M.; Landeloos, M.; Chapman, M.J.; Ninio, E.; Collen, D.; Himpens, B.; Holvoet, P. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. FASEB J. 2000, 14, 2032-2039.
23. Chen, C.H.; Jiang, T.; Yang, J.H.; Jiang, W.; Lu, J.; Marathe, G.K.; Pownall, H.J.; Ballantyne, C.M.; McIntyre, T.M.; Henry, P.D.; Yang, C.Y. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 2003, 107, 2102-2108.
24. Zalewski, A.; Macphee, C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 923-931.
25. Mohler, E.R., III; Sarov-Blat, L.; Shi, Y.; Hamamdzic, D.; Zalewski, A.; Macphee, C.; Llano, R.; Pelchovitz, D.; Mainigi, S.K.; Osman, H.; et al. Site-specific atherogenic gene expression correlates with subsequent variable lesion development in coronary and peripheral vasculature. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 850-855.
26. Mannheim, D.; Herrmann, J.; Versari, D.; Gössl, M.; Meyer, F.B.; McConnell, J.P.; Lerman, L.O.; Lerman, A. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke 2008, 39, 1448-1455.
27. Herrmann, J.; Mannheim, D.; Wohlert, C.; Versari, D.; Meyer, F.B.; McConnell, J.P.; Gössl, M.; Lerman, L.O.; Lerman, A. Expression of lipoprotein-associated phospholipase A2 in carotid artery plaques predicts long-term cardiac outcome. Eur. Heart J. 2009, 30, 2930-2938.
28. Kolodgie, F.D.; Burke, A.P.; Skorija, K.S.; Ladich, E.; Kutys, R.; Makuria, A.T.; Virmani, R. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 2523-2529.
29. Guerra, R.; Zhao, B.; Mooser, V.; Stafforini, D.; Johnston, J.M.; Cohen, J.C. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J. Lipid Res. 1997, 38, 2281-2288.
30. Lenzini, L.; Antezza, K.; Caroccia, B.; Wolfert, R.L.; Szczech, R.; Cesari, M.; Narkiewicz, K.; Williams, C.J.; Rossi, G.P. A twin study of heritability of plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity. Atherosclerosis 2009, 205, 181-185.
31. Garza, C.A.; Montori, V.M.; McConnell, J.P.; Somers, V.K.; Kullo, I.J.; Lopez-Jimenez, F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: A systematic review. Mayo Clin. Proc. 2007, 82,159-165.
32. Packard, C.J.; O'Reilly, D.S.; Caslake, M.J.; McMahon, A.D.; Cooney, J.; Macphee, C.H.; Suckling, K.E.; Krishna, M.; Wilkinson, F.E.; Rumley, A.; Lowe, G.D. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N. Engl. J. Med. 2000, 343, 1148-1155.
33. Blake, G.J.; Dada, N.; Fox, J.C.; Manson, J.E.; Ridker, P.M. A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women. J. Am. Coll. Cardiol. 2001, 38, 1302-1306.
34. Koenig, W.; Khuseyinova, N. Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiologic evidence. Cardiovasc. Drugs Ther. 2009, 23, 85-92.
35. Ballantyne, C.M.; Hoogeveen, R.C.; Bang, H.; Coresh, J.; Folsom, A.R.; Heiss, G.; Sharrett, A.R. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004, 109, 837-842.
36. Koenig, W.; Khuseyinova, N.; Lowel, H.; Trischler, G.; Meisinger, C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year followup of a large cohort from southern Germany. Circulation 2004, 110, 1903-1908.
37. Oei, H.H.; van der Meer, I.M.; Hofman, A.; Koudstaal, P.J.; Stijnen, T.; Breteler, M.M.; Witteman, J.C. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005, 111, 570-575.
38. Kiechl, S.; Willeit, J.; Mayr, M.; Viehweider, B.; Oberhollenzer, M.; Kronenberg, F.; Wiedemann, C.J.; Oberthaler, S.; Xu, Q.; Witztum, J.L.; Tsimikas, S. Oxidized phospholipids, lipoprotein (a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 1788-1795.
39. Daniels, L.B.; Laughlin, G.A.; Sarno, M.J.; Bettencourt, R.; Wolfert, R.L.; Barrett-Connor, E. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J. Am. Coll. Cardiol. 2008, 51, 913-919.
40. Jenny, N.S, Solomon, C. Cushman, M. Nelson, J.J. Tracy, R.P. Psaty, B.M. Furberg C.D. Lipoprotein-associated phospholipase A2 and cardiovascular disease: results from the Cardiovascular Health Study. Circulation 2006, 113, E-332. Abstract.
41. Caslake, M.J. Cooney, J. Murray, E. Bedford, D. Robertson, M. Nelson, J.J. Packard, C.J. Lipoprotein-associated phospholipase A2 as a risk factor for coronary vascular disease in the elderly. Atherosclerosis. 2006, 7 (Suppl.), 484. Abstract.
42. Möckel, M.; Müller, R.; Vollert, J.O.; Müller, C.; Danne, O.; Gareis, R.; Störk, T.; Dietz, R.; Koenig, W. Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin. Res. Cardiol. 2007, 96, 604-612.
43. Gerber, Y.; McConnell, J.P.; Jaffe, A.S.; Weston, S.A.; Killian, J.M.; Roger, V.L. Lipoproteinassociated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 2517-2522.
44. O'Donoghue, M.; Morrow, D.A.; Sabatine, M.S.; Murphy, S.A.; McCabe, C.H.; Cannon, C.P.; Braunwald, E.: Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006, 113, 1745-1752.
45. Oldgren, J.; James, S.K.; Siegbahn, A.; Wallentin, L. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur. Heart. J. 2007, 28, 699-704.
46. Brilakis, E.S.; McConnell, J.P.; Lennon, R.J.; Elesber, A.A.; Meyer, J.G.; Berger, P.B. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur. Heart J. 2005, 26, 137-144.
47. Koenig, W.; Twardella, D.; Brenner, H.; Rothenbacher, D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function and hemodynamic stress. Arterioscler Thromb. Vasc. Biol. 2006, 26, 1586-1593.
48. Corsetti, J.P.; Rainwater, D.L.; Moss, A.J.; Zareba, W.; Sparks, C.E. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin. Chem. 2006, 52, 1331-1338.
49. Sabatine, M.S.; Morrow, D.A.; O'Donoghue, M.; Jablonski, K.; Rice, M.M.; Solomon, S.; Rosenberg, Y.; Domanski, M.J.; Hsia, J. PEACE Investigators. Prognostic utility of lipoprotein associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 2463-2469.
50. Winkler, K.; Hoffmann, M.M.; Winkelmann, B.R.; Friedrich, I.; Schäfer, G.; Seelhorst, U.; Wellnitz, B.; Wieland, H.; Boehm, B.O.; März, W. Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Clin. Chem. 2007, 53, 1440-1447.
51. Yang, E.H.; McConnell, J.P.; Lennon, R.J.; Barsness, G.W.; Pumper, G.; Hartman, S.J.; Rihal, C.S.; Lerman, L.O.; Lerman, A. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 106-111.
52. Lavi, S.; McConnell, J.; P Rihal, C.S.; Prasad, A.; Mathew, V.; Lerman, L.O.; Lerman, A. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidlcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007, 115, 2715-2721.
53. Karakas, M.; Koenig, W. Phospholipase A2 as a therapeutic target for atherosclerosis. Clin. Lip. 2010, 5, 43-56.
54. Rosenson, R.S. Future role for selective phospolipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc. Drugs Ther. 2009, 23, 93-101.
55. Wilensky, R.L.; Shi, Y.; Mohler, E.R.; Hamamdzic, D.; Burgert, M.E.; Li, J.; Postle, A.; Fenning, R.S.; Bollinger, J.G.; Hoffmann, B.E.; et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat. Med. 2008, 14, 1015-1016.
56. Johnson, A.; Zalewski, A.; Janmohamed, S.; Sawyer, J.; Rolfe, T.; Staszkiewicz, W.; Alvarez, S. Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, an emerging CV risk marker, can be inhibited in atherosclerotic lesions and plasma by novel pharmacologic intervention: the results of a multicenter clinical study. Circulation 2004, 110, III-590.
57. Mohler, E.R.; Ballantyne, C.M.; Davidson, M.H.; Hanefeld, M.; Ruilope, L.M.; Johnson, J.L.; Zalewski, A. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 2008, 51, 1632-1641.
58. Serruys, P.W.; Garcia-Garcia, H.M.; Buszman, P.; Erne, P.; Verheye, S.; Aschermann, M.; Duckers, H.; Bleie, O.; Dudek, D.; Botker, H.E.; von Birgelen, C.; DÁmico, D.; Hutchinson, T.; Zambanini, A.; Mastik, F.; van Ees, G.A.; van der Steen, A.F.; Vince, D.G.; Ganz, P.; Hamm, C.W.; Wijns, W.; Zalewski, A. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008, 118, 1172-1182.
59. McCullough, P.A. Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target? Curr. Atheroscler. Rep. 2009, 11, 334-337.